3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 1
3
Phase 2
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
82
Lung Neoplasms
24
Brain Neoplasms
6
NSCLC
5
Meningeal Carcinomatosis
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Non Small Cell Lung Cancer Metastatic
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma
2
Adenocarcinoma of Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stage II-IIIB Non-small Cell Lung Carcinoma
1
Resectable Non-small Cell Lung Cancer
1
Rectal Neoplasms
1
Rare Tumour
1
Non-Small Cell Lung Cancer With EGFR T790M Mutation
1
Neurocognitive
1
Melanoma
1
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
1
Glioma
1
Interventions
Cisplatin
24
Carboplatin
19
Paclitaxel
18
pembrolizumab
12
Gemcitabine
12
Radiotherapy
9
Fluorouracil
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
7
cemiplimab
6
Platinum
6
Nivolumab
6
Docetaxel
6
Cetuximab
6
1,2-diaminocyclohexaneplatinum II citrate
6
epothilone B
5
anlotinib
5
Sunitinib
5
Pemetrexed
5
Oxaliplatin
5
Everolimus
5
Drug Therapy
5
Cyclophosphamide
5
Capecitabine
5
Bevacizumab
5
durvalumab
4
Radiotherapy, Intensity-Modulated
4
Radiation
4
Erlotinib Hydrochloride
4
Celecoxib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma
×
osimertinib
×
Clear all
NCT03778229
2026-04-23
SAVANNAH
AstraZeneca
Phase 2
Active not recruiting
367 enrolled
32 charts
NCT04606771
2026-02-27
CoC
AstraZeneca
Phase 2
Active not recruiting
30 enrolled
20 charts